Nucleic acid sequence related with risperidone clinical curative effect

Abstract

The invention relates to a nucleic acid sequence correlative with Risperidone clinical curative effect in gene technical sphere. The separated DNA molecule by this invention has sequence indicated in SEQ ID NO:1 and the 251th order of the indicated sequence in SEQ ID NO: 1 is mononucleotide polymorphism site rs1799978, in which the said mononucleotide polymorphism site rs1799978 names that the 251th order of the indicated sequence in SEQ ID NO: 1 exists A, the said DNA of complementary chain is T equipotential site and lies in 241th order of DRD2 gene upstream. The 251th order of the indicated sequence in SEQ ID NO: 1 is mononucleotide polymorphism site is A homozygote. Using this invention to predict Risperidone clinical curative effect does not depend on medical subjective techniques and statute of limitation is strong, and consequently is a potential tool which can be aided by clinical just drugs.

Description

technical field

[0001] The present invention relates to a nucleic acid sequence in the field of gene technology, in particular to a nucleic acid sequence related to the clinical curative effect of risperidone. Background technique

[0002] Risperidone (risperidone) is a new generation of antipsychotic drugs, developed by the Belgian Janssen Pharmaceutical Company in 1984, the trade name is Risperidal (Risperidal), which is a benzisoxazole (benzisoxazole) derivative, it is 5-HT2 receptor Compared with the first-generation antipsychotic drugs, risperidone has good curative effect on positive symptoms and negative symptoms of schizophrenia, and has adverse effects such as extrapyramidal symptoms (EPS). Low incidence of reactions (Leysen JE, Gommeren W, Eens A, De Chaffog De Coucelles D, Stoof JC, Janssen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247:661-670). In practical application, there are great individual differences in the ...